1. Home
  2. Labeler Index
  3. Valorum Biologics, Llc
  4. 85006-2908
  5. Product Images: Ahzantive

Product Images Ahzantive

View Photos of Packaging, Labels & Appearance

Table of Contents

  1. carton - Carton label
  2. Vial Label - Vial label
  3. Figure 2 - ahzantive 02
  4. figure 3 - ahzantive 03
  5. figure 4a - ahzantive 04
  6. figure 4b - ahzantive 05
  7. figure 5 - ahzantive 06
  8. figure 6 - ahzantive 07
  9. figure 7a - ahzantive 08
  10. figure 7b - ahzantive 09
  11. figure 8 - ahzantive 10
  12. figure 9 - ahzantive 11
  13. figure 10 - ahzantive 12
  14. figure 11 - ahzantive 13
  15. figure 12 - ahzantive 14
  16. Figure 1 - correct ahzantive fig07 3

Product Label Images

The following 16 images provide visual information about the product associated with Ahzantive NDC 85006-2908 by Valorum Biologics, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

carton - Carton label

carton - Carton label

Vial Label - Vial label

Vial Label - Vial label

The text provides information about a medication named Ahzantivem Rx, which is aflibercept-mrbb injection used for intravitreal use. It is specified as a single-dose vial that needs to be refrigerated. The text also includes details on the lot and expiration date printing format, manufacturing information, and specifications for label design like font type, size, and color details.*

Figure 2 - ahzantive 02

Figure 2 - ahzantive 02

figure 3 - ahzantive 03

figure 3 - ahzantive 03

figure 4a - ahzantive 04

figure 4a - ahzantive 04

figure 4b - ahzantive 05

figure 4b - ahzantive 05

figure 5 - ahzantive 06

figure 5 - ahzantive 06

figure 6 - ahzantive 07

figure 6 - ahzantive 07

figure 7a - ahzantive 08

figure 7a - ahzantive 08

figure 7b - ahzantive 09

figure 7b - ahzantive 09

This text appears to be describing instructions for dosing a solution using a flat plunger edge after removing air bubbles and excess drug. The recommended dose is 0.05 mL.*

figure 8 - ahzantive 10

figure 8 - ahzantive 10

This is a table showing the mean change in visual acuity over a period of 96 weeks for two different views (view 1 and view 2) and two different treatments (Aflibercept 2mg every 8 weeks and Ranibizumab 0.5mg every 4 weeks). The visual acuity measurements are provided at different time points in weeks.*

figure 9 - ahzantive 11

figure 9 - ahzantive 11

This text appears to contain a mix of characters and does not form a coherent description. The content is not available for evaluation.*

figure 10 - ahzantive 12

figure 10 - ahzantive 12

figure 11 - ahzantive 13

figure 11 - ahzantive 13

figure 12 - ahzantive 14

figure 12 - ahzantive 14

Figure 1 - correct ahzantive fig07 3

Figure 1 - correct ahzantive fig07 3

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.